Immatics Teams With MD Anderson On Novel Immuno-Oncology Targets

Germany's immatics biotechnologies GMBH is establishing a US subsidiary in Houston on the campus of MD Anderson Cancer Center, and the two will work together to produce new cancer immunotherapies derived from immatics' XPRESIDENT technology platform.